Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study

Ricardo L. Favaretto1 · Atessa Bahadori2 · Romain Mathieu1,3 · Andrea Haitel4 · Bernhard Grubmüller2 · Vitaly Margulis5 · Jose A. Karam6 · Morgan Rouprêt7 · Christian Seitz7 · Pierre L. Karakiewicz8 · Isabela W. Cunha1 · Stenio C. Zequi1 · Christopher G. Wood6 · Alon Z. Weizer9 · Jay D. Raman10 · Mesut Remzi2 · Nathalie Rioux-Leclercq11 · Solene Jacquet-Kammerer11 · Karim Bensalah3 · Yair Lotan5 · Alexander Bachmann12 · Michael Rink13 · Alberto Briganti14 · Shahrokh F. Shariat2,5,15

Received: 10 February 2016 / Accepted: 16 April 2016 / Published online: 29 April 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Purpose To assess the role of E-cadherin as prognostic biomarker in upper tract urothelial carcinoma (UTUC) in a large multi-institutional cohort of patients.

Methods Immunohistochemistry technique was used to evaluate E-cadherin expression in 678 patients with unilateral, sporadic UTUC treated with RNU. E-cadherin expression was considered decreased if 10% or more cells had decreased expression (<90%).

Results Decreased E-cadherin expression was observed in 353 patients (52.1%) and was associated with advanced pathological stage (P < 0.001), higher grade (P < 0.001), lymph node metastasis (P = 0.006), lymphovascular invasion (P < 0.001), concomitant carcinoma in situ (P < 0.001), multifocality (P = 0.004), tumor necrosis (P = 0.020) and sessile architecture (P < 0.001). Within a median follow-up of 30 months (interquartile range 15–57), 171 patients (25.4%) experienced disease recurrence and 150 (21.9%) died from UTUC. In univariable analyses, decreased E-cadherin expression was significantly associated with worse recurrence-free survival (P < 0.001) and cancer-specific survival CSS (P = 0.006); however, in multivariable analyses, it was not (P = 0.74 and 0.84, respectively). The lack of independent prognostic value of E-cadherin remained true in all subgroup analyses.

Ricardo L. Favaretto and Atessa Bahadori have contributed equally to this work.

Shahrokh F. Shariat
sfshariat@gmail.com

1 Department of Urology, A. C. Camargo Hospital, São Paulo, Brazil
2 Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090 Vienna, Austria
3 Department of Urology, Rennes University Hospital, Rennes, France
4 Department of Pathology, Medical University Vienna, Vienna, Austria
5 Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
6 Department of Urology, MD Anderson Cancer Center, Houston, TX, USA
7 Academic Department of Urology, Faculté de Médecine Pierre et Marie Curie, La Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, University Paris 6, Paris, France
8 Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
9 Department of Urology, University of Michigan Cancer Center, Ann Arbor, MI, USA
10 Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
11 Department of Pathology, Rennes University Hospital, Rennes, France
12 Department of Urology, University Hospital Basel, Basel, Switzerland
13 Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
14 Department of Urology, Vita Salute San Raffaele University, Milan, Italy
15 Department of Urology, Weill Cornell Medical College, New York, NY, USA
Conclusion In UTUC patients treated with RNU, decreased E-cadherin expression is associated with features of biologically and clinically aggressive disease and worse outcome in univariable, but not multivariable, analyses. If E-cadherin’s association with factors of advanced disease is confirmed on UTUC biopsy specimens, it could be used to help in the clinical decision-making regarding kidney-sparing approaches and/or neo-adjuvant chemotherapy.

Keywords E-cadherin · Urothelium · Carcinoma · Recurrence · Prognosis · Survival · Prediction

Abbreviations
UTUC  Upper tract urothelial carcinoma
RFS  Recurrence-free survival
CSS  Cancer-specific survival
RNU  Radical nephroureterectomy
UCB  Urothelial carcinoma of the bladder
EMT  Epithelial–mesenchymal transition
LVI  Lymphovascular invasion
CI  Confidence interval
HR  Hazard ratio

Introduction
Upper tract urothelial carcinoma (UTUC) is a rare disease, accounting for 5–10 % of all urothelial carcinomas [1]. In the last two decades, management of UTUC has improved but still remains challenging. Radical nephroureterectomy (RNU) remains the standard treatment for non-metastatic disease [1, 2]. However, kidney-sparing approaches are now considered for low-risk UTUC, and conversely, regional lymphadenectomy and perioperative chemotherapy are discussed in addition to RNU for high-risk UTUC [1, 2]. Current concerns lay in the identification of the patients who may benefit from these treatments. Recent evidence suggests that carcinogenetic mechanisms in UTUC are different from urothelial carcinoma of the bladder (UCB) [2–4]. Therefore, molecular alterations from one setting may not be extrapolated in the other. In this regard, specific validation of biomarkers in UTUC is mandatory to develop predictive tools that could allow accurate clinical decision-making in the management of UTUC patients.

Decreased expression of the membrane-associated glycoprotein E-cadherin has been established as a feature of epithelial–mesenchymal transition (EMT) in epithelial malignancies [5–7]. In normal cells, E-cadherins’ cytoplasmic domain binds with subtypes β or γ of the catenin proteins, which in turn secure attachment to the actin microfilament, thus ensuring cytoskeleton integrity and stable cellular adhesion [8]. Loss of cellular adhesion is a tipping point in tumor progression resulting in poorly differentiated and invasive tumors [7, 8]. E-cadherin has been shown to be an independent prognostic factor in UCB [3, 9]. In UTUC, single-center studies with small cohorts have investigated the role of E-cadherin expression with conflicting results [10–15]. We hypothesized that E-cadherin expression in RNU specimens was associated with features of biologically and clinically aggressive UTUC, thereby potentially helping in the clinical decision-making of UTUC patients. To assess this hypothesis, we tested the association of E-cadherin with pathologic characteristics and prognosis in a large multi-institutional cohort of patients treated by RNU for UTUC.

Materials and methods
Patient selection
This was a retrospective, institutional review board-approved study involving seven institutions from the international UTUC collaboration [16]. The initial study cohort comprised 753 patients who underwent RNU for UTUC (Ta–T4 N0–1 M0) between March 1990 and May 2008. Exclusion criteria included neo-adjuvant chemotherapy/radiotherapy and follow-up <3 months, resulting in a final cohort of 678 patients.

Data collection, pathological evaluation and immunochemistry
A computerized database was used to collect patient and tumor characteristics. All surgical specimens were processed according to standard pathological procedures. Original pathology slides were centrally collected and analyzed by genitourinary pathologists blinded to clinical outcome. Pathological stage was determined according to the 2002 tumor, node and metastasis (TNM) staging system, and the pathological grading using the 1998 WHO/ISUP consensus classification. The tumors were architecturally defined as papillary or sessile [17]. The presence of tumor cells within an endothelium-lined space without underlying muscular walls was defined as lymphovascular invasion (LVI) [18]. Multifocal tumor [19], carcinoma in situ and tumor necrosis [20] were confirmed in every slide.

E-cadherin staining was performed on formalin-fixed tissue microarray slides constructed for the study in a single laboratory, as described previously [9]. Antigen retrieval was performed and the primary anti-E-CD monoclonal mouse antibody (Transduction Labs, dilution 1:25 in blocking solution) was incubated for 1 h. Secondary antibody (Vector Labs) was applied at a dilution of 1:400. Reactivity was visualized with an avidin–biotin complex immunoperoxidase system using diamino benzidine as the chromogen.
and methyl green and alcian blue as the counterstain. Positive controls included bladder and prostate tissue known to possess 100% preserved E-cadherin expression (external control) and normal urothelium (internal control) included in cancer specimens. Negative controls were serial sections processed without incubation in primary antibody. Areas of urothelial tumor were classified as normal (90–100% cells with preserved cell border staining resembling membranous staining of normal controls) and abnormal, which included negative (0–10% positive tumor cells) and various degrees of heterogeneous decreased expression (11–89% positive tumor cells) (Fig. 1). Multiple sections from the same patient were evaluated to minimize the effect of the staining technique on interpretation. The negative and the heterogeneously staining tumors were considered together in statistical calculations based on the premise that the negative areas of the heterogeneous tumors would define the biological behavior of the tumor as a whole [9, 21].

Management and follow-up

All patients underwent standard RNU [1]. Additionally, a regional lymphadenectomy was performed in 155 patients (22.9%) and 68 patients (10%) received adjuvant chemotherapy. Postoperative follow-up was generally performed every 3 months the first year after surgery, every 6 months in the second year and annually thereafter. Relapse was defined by local recurrence or distant metastasis. Cause of death was determined by chart review or death certificate [22].

Statistical analyses

Outcomes included recurrence-free survival (RFS) and cancer-specific survival (CSS). Chi-square test was used to assess decreased E-cadherin expression with categorical variables. Differences in continuous variables were analyzed using Kruskal–Wallis tests. The Kaplan–Meier method was used to estimate RFS and CSS; log-rank tests were applied for pairwise comparison of survival. Univariable and multivariable Cox regression models addressed associations of RFS and CSS with potential prognostic factors. We performed subgroup analyses in patients with pTa–pT4 high-grade disease, pTa–pT2 N0/Nx, pT1–pT3 N0/Nx, pT3/pT4 N0/Nx, pTa–pT4 pN0 and pTa–pT4 pN1 disease. All P values were two-sided, and statistical significance was defined as P < 0.05. Statistical analyses were performed using Stata 11.0 statistical software (StataCorp., College Station, TX, USA).

Results

Descriptive characteristics and association with pathology

Decreased E-cadherin expression was observed in 353 patients (52.1%). There was a significant association between decreased E-cadherin expression and pathological adverse features such as advanced pathological tumor stage.
(P < 0.001), high pathological tumor grade (P < 0.001), lymph node metastases (P = 0.006), LVI (P < 0.001), concomitant carcinoma in situ (P < 0.001), multifocality (P = 0.004), tumor necrosis (P = 0.020) and sessile architecture (P < 0.001) (Table 1).

### Association of decreased E-cadherin expression with cancer recurrence and cancer-specific survival

The median follow-up time was 30 months (15–57). Within this period, 171 patients (25.4 %) experienced disease recurrence and 150 (21.9 %) died from UTUC. In univariable analyses, decreased E-cadherin expression was associated with a higher probability of disease recurrence (log-rank test P < 0.001, HR 1.69, 95 % CI 1.23–2.30) (Fig. 2a) and cancer-specific mortality (log-rank test P = 0.006, HR 1.57, 95 % CI 1.13–2.19) (Fig. 2b). Table 2 summarizes the Cox regression analyses. In multivariable analyses, decreased E-cadherin expression was not associated independently with either RFS (HR 1.06, P = 0.74) or CSS (HR 0.96, P = 0.84) (Table 2).

Further univariable analyses in subgroups of patients revealed that decreased E-cadherin expression was associated with worse outcomes in patients with pTa–pT4 M0 high-grade tumors (HR 1.55, P < 0.011) and pTa–pT2 pN0/ Nx M0 tumors (HR 2.20, P < 0.038) regarding RFS and in patients with pTa–pT4 M0 high-grade tumors (HR 1.50, P < 0.025) regarding CSS. However, in these subgroups, the prognostic value of E-cadherin did not retain statistical significance when adjusted for the effects of standard clinicopathological features.

### Discussion

In this study, we assessed the clinical significance of a decreased E-cadherin expression in an international cohort of 678 UTUC patients treated with RNU. We found that decreased E-cadherin expression in tumor cells is associated with adverse clinicopathological features and worse outcomes.

Half of the patients in this cohort presented with decreased expression of E-cadherin in the tumor. This was within the range previously reported in UCB patients (31–77 %) [8, 9] but lower than that reported in UTUC patients (68–71 %) [10, 11]. This could be due to our lower proportion of high stage tumors compared to the two other studies (50 vs. 54 and 61 %), as well as methodological differences in scoring, staining protocols, choice of antibody and/or antigen retrieval.

Patients with decreased E-cadherin were most likely to harbor tumors with features of biologically aggressive disease. This association is in line with the biological role of E-cadherin, as a calcium-dependent glycoprotein essential to epithelial tissue integrity. Loss of cellular adhesion results in the detachment of cancerous cells from the primary lesion, promoting invasiveness [23]. In carcinoma in situ of the bladder, for example, loss of E-cadherin expression predicts RFS, disease progression and CSS [21]. Similar results were reported in various UCB studies.

### Table 1 Association of decreased E-cadherin expression with clinicopathological characteristics in 678 patients treated with radical nephroureterectomy for upper tract urothelial carcinoma

| Characteristics                  | All patients | Normal E-cadherin | Decreased E-cadherin | P     |
|----------------------------------|--------------|-------------------|----------------------|-------|
| Total, n (%)                     | 678          | 325 (47.9)        | 353 (52.1)           | 0.19  |
| Age (years)                      |              |                   |                      |       |
| Median (IQR)                     | 69 (63–76)   | 69 (62–76)        | 70 (63–77)           |       |
| Gender, n (%)                    |              |                   |                      | 0.78  |
| Male                             | 380 (56.1)   | 184 (56.6)        | 196 (55.5)           |       |
| Female                           | 298 (43.9)   | 141 (43.4)        | 157 (44.5)           |       |
| Tumor stage, n (%)               |              |                   |                      | <0.001|
| pTa                              | 121 (17.8)   | 82 (25.2)         | 39 (11.1)            |       |
| pT1                              | 208 (30.7)   | 98 (30.1)         | 110 (31.2)           |       |
| pT2                              | 123 (18.1)   | 60 (18.5)         | 63 (17.8)            |       |
| pT3                              | 193 (28.5)   | 74 (22.8)         | 119 (33.7)           |       |
| pT4                              | 33 (4.9)     | 11 (3.4)          | 22 (6.2)             |       |
| Grade, n (%)                     |              |                   |                      | <0.001|
| Low                              | 174 (25.6)   | 114 (35.1)        | 60 (17.0)            |       |
| High                             | 504 (74.3)   | 211 (64.9)        | 293 (83.0)           |       |
| Lymph node status, n (%)         |              |                   |                      | 0.006 |
| pNx                              | 523 (77.2)   | 261 (80.3)        | 262 (74.2)           |       |
| pN0                              | 108 (15.9)   | 52 (16)           | 56 (15.9)            |       |
| pN1                              | 47 (6.9)     | 12 (3.7)          | 35 (9.9)             |       |
| Lymphovascular invasion, n (%)   |              |                   |                      | <0.001|
| Yes                              | 135 (19.9)   | 26 (8.0)          | 109 (30.9)           |       |
| No                               | 543 (80.1)   | 299 (92.0)        | 244 (69.1)           |       |
| Concomitant carcinoma in situ, n |              |                   |                      | <0.001|
| Yes                              | 128 (18.9)   | 41 (12.6)         | 87 (24.7)            |       |
| No                               | 550 (81.1)   | 284 (87.4)        | 266 (75.3)           |       |
| Multifocality, n (%)             |              |                   |                      | 0.004 |
| Yes                              | 145 (21.4)   | 54 (16.6)         | 91 (25.8)            |       |
| No                               | 533 (78.6)   | 271 (83.4)        | 262 (74.2)           |       |
| Necrosis, n (%)                  |              |                   |                      | 0.020 |
| Yes                              | 81 (11.9)    | 29 (8.9)          | 52 (14.7)            |       |
| No                               | 597 (88.1)   | 296 (91.1)        | 301 (85.3)           |       |
| Architecture, n (%)              |              |                   |                      | <0.001|
| Papillary                        | 558 (82.3)   | 293 (90.1)        | 265 (75.1)           |       |
| Sessile                          | 120 (17.7)   | 32 (9.9)          | 88 (24.9)            |       |
| Location                         |              |                   |                      | 0.70  |
| Kidney                           | 478 (70.5)   | 232 (71.4)        | 246 (69.7)           |       |
| Ureter                           | 200 (29.5)   | 93 (28.6)         | 107 (30.3)           |       |
and one UTUC study [10]: loss of E-cadherin immunoreactivity strongly correlated with advanced stage and high-grade tumors.

We further evaluated the relevance of E-cadherin as a biomarker to predict outcomes after RNU. The role of E-cadherin expression as a prognostic factor in urothelial carcinoma was supported by previous studies mainly focusing on UCB [8, 9, 24–27]. Our results confirm that decreased E-cadherin expression is indeed associated with a higher probability of disease recurrence and cancer-specific
mortality in UTUC. However, when adjusted for the effects of established prognostic factors in multivariable analyses, E-cadherin expression lost its independent prognostic value and, therefore, may have only limited value in clinical practice. Previous studies that addressed the relationship between E-cadherin and outcomes in UTUC led to conflicting results. Fromont et al. [14] showed, in a cohort of 62 UTUC patients, that decreased E-cadherin expression was an independent prognostic factor for disease-free and overall survival. Conversely, most of the studies published thereafter with larger cohorts failed to demonstrate independent association between E-cadherin expression and disease recurrence after RNU [10–13].

Consistent with the literature [10–13], we found, in our subgroup analysis that, E-cadherin failed to demonstrate any independent prognostic value, outlining its strong association with other established pathological prognostic factors. We found a significant association between E-cadherin expression and adverse clinicopathological features such as advanced pathological tumor stage, high pathological tumor grade, lymph node metastases, LVI, concomitant carcinoma in situ, multifocality, tumor necrosis and sessile architecture. All these factors have been independently associated with worse outcome in UTUC [1, 2, 19, 20, 28–30].

The biological and clinical roles of the E-cadherin-related pathways in urothelial carcinomas are yet to be understood. Indeed, the regulation of E-cadherin is linked to many different biomarkers [2, 3]. Some of them have been already assessed in UTUC. Among them, Snail, a transcription factor is thought to repress the transcription of E-cadherin by binding to elements found in the E-cadherin promoter [12]. An increased Snail expression has been reported as an independent prognostic predictor of recurrence-free and CSS [12]. During EMT, it is thought that transcriptional regulation results in suppression of epithelial markers and gain of mesenchymal markers [7, 12]. This process recognized in different types of cancer including bladder cancer [31, 32] and UTUC [11] has been observed between epithelial E-cadherin and mesenchymal N-cadherin and has been termed the “cadherin switch.” The novel genotype results in an alteration of normal tissue architecture and high-grade, invasive tumors. To our knowledge, only one study by Muramaki et al. [11] addressed the role of N-cadherin expression in UTUC: In this study including 59 patients, N-cadherin expression was an independent prognostic factor of intra- and extra-vesical recurrence after RNU. Combining several biomarkers may help characterize the different pathways involved in tumor aggressiveness and create a prediction algorithm that would improve prognostication, clinical outcome and thus patient survival [33]. At this time the ideal combination of biomarkers remains unfortunately elusive. From the bladder cancer literature and some preliminary upper urinary tract literature, cell cycle markers (p53, pRB, p21, p27 and cyclins), apoptosis markers (Fas, caspase-3, Bcl-2 and survivin) and proliferation markers (Ki67) may be used for a combined approach [34]. Snail expression, N-cadherin expression, AKT

Table 2 Multivariable Cox regression analyses predicting disease recurrence and cancer-specific mortality of 678 patients treated with radical nephroureterectomy for upper tract urothelial carcinoma

|                        | Disease-free survival | Cancer-specific survival |
|------------------------|-----------------------|-------------------------|
|                        | HR 95 % CI            | P value HR 95 % CI      | P value |
| Male gender            | 0.76 0.56–1.04        | 0.085 0.78 0.56–1.08    | 0.13    |
| Age                    | 1.02 0.99–1.03        | 0.052 1.03 1.01–1.04    | 0.006   |
| Pathological stage     |                       |                         |         |
| Ta                     | Ref.                  |                         |         |
| T1                     | 1.80 0.76–4.28        | 0.184 1.48 0.57–3.80    | 0.42    |
| T2                     | 3.58 1.52–8.44        | 0.003 3.49 1.40–8.73    | 0.008   |
| T3                     | 7.31 3.21–16.65       | <0.001 6.29 2.58–15.31  | <0.001  |
| T4                     | 32.98 12.81–84.87     | <0.001 25.16 9.11–69.53 | <0.001  |
| Pathological high grade| 1.38 0.82–2.32        | 0.23 1.59 0.89–2.82     | 0.12    |
| Lymphovascular invasion| 1.14 0.80–1.64        | 0.47 1.31 0.89–1.92     | 0.16    |
| Concomitant CIS        | 1.52 1.03–2.23        | 0.035 1.06 0.69–1.63    | 0.78    |
| Architecture           | 1.27 0.86–1.86        | 0.23 1.35 0.89–2.06     | 0.15    |
| Necrosis               | 0.46 0.29–0.75        | 0.002 0.51 0.30–0.85    | 0.009   |
| Multifocality          | 1.44 1.01–2.056       | 0.045 1.78 1.22–2.58    | 0.003   |
| Kidney location        | 1.17 0.86–1.60        | 0.32 1.26 0.90–1.76     | 0.18    |
| Lymph node metastasis  | 2.40 1.57–3.66        | <0.001 2.28 1.46–3.55   | <0.001  |
| E-cadherin decreased expression | 1.06 0.76–1.48 | 0.74 0.96 0.68–1.38    | 0.84    |

CI confidence interval, CIS carcinoma in situ, HR hazard ratio
pathway, β- or γ-catenins and matrix metalloproteinases are molecular markers associated with EMT that could be analyzed in a combined approach with E-cadherin expression.

We acknowledge that our study has some limitations. First and foremost are those related to its retrospective nature and the immunohistochemical technique. Indeed, this latter technique may be associated with a lack of reproducibility related to the choice of antibodies, the specimen handling procedures, technical demands and scoring protocols. However, tissue microarray with staining protocols and automated scoring systems based on bright field microscopy imaging coupled with advanced color detection software were used to overcome these common limitations. Finally, decreased expression of E-cadherin was defined according to a standard cutoff used in UCB and use of new thresholds may have led to different conclusions.

Conclusion

Decreased E-cadherin expression is associated with adverse clinicopathological UTUC features and worse outcomes in univariable analyses. E-cadherin expression is, however, not an independent prognostic factor when adjusted for the effects of established prognostic factors, limiting its use in clinical decision-making regarding prognosis after RNU. If E-cadherin’s association with factors of advanced disease is confirmed on UTUC biopsy specimens, it could be used to help in the clinical decision-making regarding kidney-sparing approaches and/or neo-adjuvant chemotherapy.

Acknowledgments

Open access funding provided by Medical University of Vienna.

Authors’ contributions

Ricardo L. Favaretto and Atessa Bahadori collected, managed and analyzed the data, and wrote and edited the manuscript; Vitaly Margulis developed the protocol, collected and managed the data, and edited the manuscript; Jose A. Karam and Christopher G. Wood collected the data and edited the manuscript; Morgan Rouprêt, Pierre I. Karakiewicz, Alberto Briganti, Michael Rink, Alon Z. Weizer, Jay D. Raman, Isabella W. Cunha, Steenio C. Zequi and Karim Bensalah collected the data and edited the manuscript; Morgan Rouprêt, Pierre I. Karakiewicz, Alberto Briganti, Michael Rink, Alon Z. Weizer, Jay D. Raman, Isabella W. Cunha, Steenio C. Zequi and Karim Bensalah collected the data and edited the manuscript; Romain Mathieu edited the manuscript; Andrea Haitel collected the data; Morgan Rouprêt, Pierre I. Karakiewicz, Alberto Briganti, Michael Rink, Alon Z. Weizer, Jay D. Raman, Isabella W. Cunha, Steenio C. Zequi and Karim Bensalah collected the data; Yair Lotan developed the project, collected, managed and analyzed the data, and wrote and edited the manuscript.

Compliance with ethical standards

Conflict of interest

The authors disclose no competing interests.

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Böhle A, Van Rhijn BW, Kaasinen E, Palou J, Shariat SF (2013) European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 63(6):1059–1071
2. Lugezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, Shariat SF, Wood CG, Zigeuner R (2012) Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 62(1):100–114
3. Yates DR, Catto JW (2013) Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours. World J Urol 31(1):21–29
4. Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, Karakiewicz PI, Scherr DS, Shariat SF (2013) Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 189(4):1214–1221
5. Van Roy F, Berx G (2008) The cell–cell adhesion molecule E-cadherin. Cell Mol Life Sci 65(23):3756–3788
6. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Shiptsins M, Campbell LL, Polyak K, Briskin C, Yang J, Weinberg RA (2008) The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715
7. Baumgart E, Cohen MS, Silva Neto B, Jacobs MA, Wotkowicz C, Rieger-Christ KM, Biolo A, Zeheb R, Loda M, Libertino JA, Summerhayes IC (2007) Identification and prognostic significance of an epithelial–mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 13(6):1685–1694
8. Clairotte A, Lascombe I, Faouconnet S, Mauny F, Félix S, Algros MP, Bittard H, Kantelip B (2006) Expression of E-cadherin and α-, β-, γ-catenins in patients with bladder cancer identification of γ-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol 125(1):119–126
9. Byrne RR, Shariat SF, Brown R, Kattan MW, Morton RA, Wheeler TM, Lerner SP (2001) E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term follow-up. J Urol 165(5):1473–1479
10. Nakanishi K, Kawai T, Torikata C, Aures T, Ikeda T (1997) E-cadherin expression in upper-urinary-tract carcinoma. Int J Cancer 74(4):446–449
11. Muramaki M, Miyake H, Terakawa T, Kusuda Y, Fujisawa M (2011) Expression profile of E-cadherin and N-cadherin in urothelial carcinoma of the upper urinary tract is associated with disease recurrence in patients undergoing nephroureterectomy. Urology 78(6):1443–e7
12. Kosaka T, Kikuchi E, Mikasu S, Miyajima A, Shirotate S, Ishida M, Okada Y, Oya M (2010) Expression of snail in upper urinary tract urothelial carcinoma: prognostic significance and implications for tumor invasion. Clin Cancer Res 16(23):5814–5823
13. Jeon HG, Jeong IG, Bae J, Lee JW, Won JK, Paik JH, Kim HH, Lee SE, Lee E (2010) Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. Urology 76(2):513–e7
14. Fromont G, Rouprêt M, Amira N, Sibony M, Vallancien G, Validire P, Cussenot O (2005) Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and
19. Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, Novara G, Karakiewicz PI, Shariat SF (2011) Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol 8(8):440–447

20. Otto W, Shariat SF, Fritzsche HM, Gupta A, Matsumoto K, Kassouf W, Martignoni G, Walton TJ, Tritschler S, Baba S, Bastian PJ, Martinez-Salamanca JI, Seitz C, Pycha A, Burger M, Karakiewicz PI, Ficarra V, Novara G (2011) Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. World J Urol 29(4):487–494

21. Zieguner R, Schratt SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zieguner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Walton TJ, Pycha A, Ficarra V, Karakiewicz PI, Zieguner R, Pummer K, Schratt SF (2012) The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 61(2):245–253

22. Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK, Lotan F, Schratt SF (2012) Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol 61(4):854–855

23. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Löchner D, Birchmeier W (1991) E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113(1):173–185

24. Bryan RT, Atherfold PA, Yeo Y, Jones LJ, Harrison RF, Wallace DMA, Jankowski JA (2008) Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. J Pathol 215(2):184–194

25. Erdemir F, Ozcan F, Kılıcaslan I, Parlaktaş BS, Ulucak N, Gokce O (2007) The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma. Int Urol Nephrol 39(4):1031–1037

26. Han B, Cui D, Jing Y, Hong Y, Xia S (2012) Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch. World J Urol 30(6):861–867

27. Hu X, Ruan Y, Cheng F, Yu W, Zhang X, Larré S (2011) p130Cas, E-cadherin and β-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance. Int J Urol 18(9):630–637

28. Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, Novara G, Karakiewicz PI, Shariat SF (2011) E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology 79(2):60–65

29. Reis ST, Leite KR, Mosconi Neto A, Pontes Júnior J, Viana NL, Antunes AA, Dall’Oglio MF, Srougi M (2012) Immune expression of E-cadherin and α, β and γ-catenin adhesion molecules and prognosis for upper urinary tract urothelial carcinomas. Int Braz J Urol 38(4):466–473

30. Mathieu R, Klatte T, Margulis V, Karam JA, Rouprê M, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haite A, Bensalah K, Lotan Y, Rink M, Kloth LA, Scherr DS, Robinson BD, Shariat SF (2015) Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol 33(11):495.e15–22

31. Bryan RT, Atherfold PA, Yeo Y, Jones LJ, Harrison RF, Wallace DMA, Jankowski JA (2008) Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. J Pathol 215(2):184–194

32. Langner C (2010) Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 57(4):575–581

33. Bryan RT, Tselepis C (2010) Cadherin switching and bladder cancer. J Urol 184(2):423–431

34. Lascombe I, Clairotte A, Fauconnet S, Bernardini S, Wallerand H, Kantele B, Bittard H (2006) N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin Cancer Res 12(9):2780–2787

35. Bensalah K, Montorsi F, Shariat SF (2007) Challenges of cancer biomarker profiling. Eur Urol 52(6):1601–1609

36. Reis ST, Leite KR, Mosconi Neto A, Pontes Júnior J, Viana NL, Antunes AA, Dall’Oglio MF, Srougi M (2012) Immune expression of E-cadherin and α, β and γ-catenin adhesion molecules and prognosis for upper urinary tract urothelial carcinomas. Int Braz J Urol 38(4):466–473

37. Mathieu R, Klatte T, Margulis V, Karam JA, Rouprê M, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haite A, Bensalah K, Lotan Y, Rink M, Kloth LA, Scherr DS, Robinson BD, Shariat SF (2015) Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol 33(11):495.e15–22

38. Mathieu R, Klatte T, Margulis V, Karam JA, Rouprê M, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haite A, Bensalah K, Lotan Y, Rink M, Kloth LA, Scherr DS, Robinson BD, Shariat SF (2015) Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol 33(11):495.e15–22

39. Reis ST, Leite KR, Mosconi Neto A, Pontes Júnior J, Viana NL, Antunes AA, Dall’Oglio MF, Srougi M (2012) Immune expression of E-cadherin and α, β and γ-catenin adhesion molecules and prognosis for upper urinary tract urothelial carcinomas. Int Braz J Urol 38(4):466–473

40. Mathieu R, Klatte T, Margulis V, Karam JA, Rouprê M, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haite A, Bensalah K, Lotan Y, Rink M, Kloth LA, Scherr DS, Robinson BD, Shariat SF (2015) Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol 33(11):495.e15–22